$612 | SAVE $83 | Single User
$1228 | SAVE $167 | Global License

Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Jun 2013 | 46 | In Stock
Related Topics: AstraZeneca , Boehringer Ingelheim , FDA , Lilly , Pfizer

Introduction

Scope


With the diabetes market an important therapeutic area for a host of pharmaceutical manufacturers, this week's Physician Views poll will seek feedback from US-based endocrinologists on three key recent developments – discussion regarding pancreatic cancer/pancreatitis risk associated with incretin mimetic diabetes treatments, the role of the FDA in approving new diabetes treatments and the recent launch of Johnson & Johnson's Invokana – the first-in-class SGLT-2 inhibitor.


Last week, the FDA and manufacturers appeared to reach consensus in agreeing that additional data from much larger outcomes studies is required to allay concerns that incretin mimetic treatments are associated with pancreatic risk. The suggestion among analysts is that such sentiment has removed a significant overhang from a number of manufacturers and could help to support increased growth momentum moving into the second half of the year.


Assessing the full impact of these concerns at the physician level remains difficult, but a previous poll run by FirstWord indicates that there has been a moderate increase in caution towards the incretin mimetic therapies. Will endocrinologists be more assured in light of the FDA's measured approach to assessing this risk?


Similarly, this week's poll will also seek to gain further physician feedback regarding the FDA's stance towards diabetes treatments in general – a pertinent issue given a series of recent events; the rejection of Novo Nordisk's Tresiba in February, re-evaluation of Avandia's clinical restrictions at the beginning of June (see Spotlight On: The Avandia legacy and evolution of the FDA’s safety stance) and the administration's aforementioned evaluation of pancreatic risk associated with DPP-4 and GLP-1 treatments.


Lastly, this week's poll will seek to gain additional colour on suggestions – borne from early prescription data trends – that Johnson & Johnson's Invokana is enjoying a stronger than expected launch in the US. Somewhat downplayed by analysts, the SGLT-2 inhibitor class is now rapidly gaining in credibility – an important trend not only for Johnson & Johnson, but a number of other companies developing competing products, such as AstraZeneca/Bristol-Myers Squibb, Eli Lilly/Boehringer Ingelheim and Merck & Co./Pfizer. See ViewPoints: Have analysts undervalued the SGLT-2 diabetes drug class?


Puchase Reasons


Specifically, this week’s FirstWord Physicians View poll will ask US-based endocrinologists:


  • How their prescribing of DPP-4 and GLP-1 products may shift in light of the FDA’s recent assessment of possible pancreatic risk

  • What their perception is of the FDA in allowing/preventing access to new diabetes therapies

  • Whether their initial experience with Johnson & Johnson’s Invokana has matched, exceeded or missed expectation

  • What factors are driving their use of Invokana

  • What share of the oral type 2 diabetes market they expect SGLT-2 inhibitors to assumed in two years time
  • Table of Contents
    for Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class [Published by FirstWord Pharma]

    Additional Details

    Publisher

    FirstWord Pharma

    Publisher Information

    Reference

    46 |

    Report Format

    PDF

    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    SAVE 12% today! Physician Views: Can the launch of ViiV Healthcare's dolutegravir disrupt Gilead's dominance in the HIV market?
    ScopeBased on current timelines, the FDA is poised to approve the HIV therapy dolutegravir later thi...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Will generic Copaxone have traction in the MS market given emergence of oral therapies?
    ScopeA recent ruling by the US Court of Appeals for the Federal Circuit has increased the likelihood...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
    ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Which diabetes company does the best marketing job? What is key for companies launching products?
    ScopeThe importance of marketing is increasingly coming to the fore as diabetes-focused companies ba...
    01 Aug 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Post ADA view on key diabetes market developments
    ScopeLast week’s American Diabetes Association (ADA) meeting provided further evidence that the diab...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Biosimilar Remicade poised for approval in Europe – are rheumatologists and gastroenterologists ready?
    ScopeThe recent recommendation to approve a biosimilar version of Merck & Co./Johnson & Johnson's Re...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Do EU pulmonologists anticipate rapid uptake for GSK’s Seretide-successor?
    ScopeAs GlaxoSmithKline's Relvar Ellipta – a once-daily successor to its multi-billion dollar Sereti...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Key developments in the European diabetes market - will endocrinologists embrace Tresiba and Forxiga? – both rejected by the FDA
    ScopeEuropean-based endocrinologists are currently getting to grips with two new products that have ...
    01 Jul 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
    ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
    01 Jun 2013 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info
    SAVE 12% today! Surveying Physician Uptake of Mobile Devices and Apps
    IntroductionThe latest medical application software is increasing physicians’ use of mobile technolo...
    01 Oct 2012 by FirstWord Pharma USD $612 (normally
    USD $695)
    More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Physician Views: Recent developments in US diabetes market – impact of safety concerns & emergence of SGLT-2 drug class [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types

    Payment

    Buy now using our secure payment system.

    We Stock...